Multicentre preclinical profiling of apramycin for the treatment of nontuberculous mycobacteria.

ABSTRACT:

Background

Current treatment regimens for nontuberculous mycobacteria (NTM) infections, especially Mycobacterium abscessus, have suboptimal clinical outcomes, demanding novel therapeutic options. The aminoglycoside apramycin (APR) has been suggested as a therapeutic alternative to amikacin (AMK). Here, we report experimental data as part of an ongoing preclinical assessment of APR.

Methods

Antimicrobial activity against 828 isolates comprising the clinically most relevant NTM species were determined by broth microdilution. Bactericidal activity and killing kinetics of APR were determined across a variety of assay conditions against rough and smooth M. abscessus isolates in vitro and in vivo.

Findings

Both the MIC₉₀ and tentative epidemiological cutoff (TECO

SUBMITTER: Nguyen MH 

PROVIDER: S-EPMC12804157 | biostudies-literature | 2026 Jan

REPOSITORIES: biostudies-literature